CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032
The global CAR-T cell therapy market size is expected to reach USD 118,680.68 million by 2032, according to a new study by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The CAR-T cell therapy market is experiencing significant growth as it utilizes the immune system to combat cancer. This groundbreaking approach involves modifying a patient's own T cells, a type of white blood cell, to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T cells to recognize and target specific antigens in cancer cells, leading to their destruction. CAR-T therapy has shown promising results in treating specific blood malignancies and is being explored for its potential in other types of cancer.
In CAR-T treatment, T cells from the patient's blood are taken out and genetically modified in a lab to produce receptors that bind to proteins prevalent in cancer cells. Large quantities of these modified CAR-T cells are then produced and administered to the patient. By enhancing the T cells' ability to locate and attack cancer cells, CAR-T therapy has the potential to revolutionize cancer treatment.
However, the COVID-19 pandemic has impacted the CAR-T cell therapy market. Lockdowns and disruptions in the supply chain have resulted in delays and interruptions in the production and availability of raw materials needed for CAR-T cell manufacturing. This has created challenges for life science and biopharma companies, causing them to wait for new raw materials for CAR-T cell production. Efforts are underway to address these supply chain issues and ensure a steady supply of materials to support the manufacturing of CAR-T cells during these challenging times.
CAR-T Cell Therapy Market Report Highlights
CD19/CD22 is the CAR-T cell therapy with the largest market share. It has shown remarkable clinical results in leukemia and lymphoma treatment, gaining regulatory approval and proving effective in achieving patient remission.
DLBCL (Diffuse Large B-cell Lymphoma) is a prominent indication in the CAR-T cell therapy market, holding a significant market share. This fast-growing cancer of B-cell origin is a prevalent form of non-Hodgkin lymphoma affecting the lymphatic system.
North America is set to lead the market, driven by rising cancer incidence and the growing biotechnology industry. The region's demand for cancer treatments is increasing accordingly.
The global key market players include Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.
Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:
CAR-T Cell Therapy, Target Antigen Outlook (Revenue - USD Million, 2019 - 2032)
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
CAR-T Cell Therapy, Indication Outlook (Revenue - USD Million, 2019 - 2032)
DLBCL
ALL
CLL
MM
FL
Mastozytosis
Myeloid Fibrosis
MLL
Thymic Cancer
Glioblastoma
AML
Others
CAR-T Cell Therapy, Regional Outlook (Revenue - USD Million, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Austria
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Rest of Middle East & Africa
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global CAR-T Cell Therapy Market Insights
- 4.1. CAR-T Cell Therapy Market – Industry Snapshot
- 4.2. CAR-T Cell Therapy Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rise in awareness regarding CAR T-cell therapy
- 4.2.1.2. Increase in demand of ideal therapeutics for treatment of cancer
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost of CAR T-cell therapies
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. CAR-T Cell Therapy Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global CAR-T Cell Therapy Market, by Target Antigen
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2019-2032 (USD Million)
- 5.3. CD19/CD22
- 5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2019-2032 (USD Million)
- 5.4. BCMA (B-Cell Maturation Antigen)
- 5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2019-2032 (USD Million)
- 5.5. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
- 5.5.1. Global CAR-T Cell Therapy Market, by Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY), by Region, 2019-2032 (USD Million)
- 6. Global CAR-T Cell Therapy Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 6.3. DLBCL
- 6.3.1. Global CAR-T Cell Therapy Market, by DLBCL, by Region, 2019-2032 (USD Million)
- 6.4. ALL
- 6.4.1. Global CAR-T Cell Therapy Market, by ALL, by Region, 2019-2032 (USD Million)
- 6.5. CLL
- 6.5.1. Global CAR-T Cell Therapy Market, by CLL, by Region, 2019-2032 (USD Million)
- 6.6. MM
- 6.6.1. Global CAR-T Cell Therapy Market, by MM, by Region, 2019-2032 (USD Million)
- 6.7. FL
- 6.7.1. Global CAR-T Cell Therapy Market, by FL, by Region, 2019-2032 (USD Million)
- 6.8. Mastozytosis
- 6.8.1. Global CAR-T Cell Therapy Market, by Mastozytosis, by Region, 2019-2032 (USD Million)
- 6.9. Myeloid Fibrosis
- 6.9.1. Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, by Region, 2019-2032 (USD Million)
- 6.10. MLL
- 6.10.1. Global CAR-T Cell Therapy Market, by MLL, by Region, 2019-2032 (USD Million)
- 6.11. Thymic Cancer
- 6.11.1. Global CAR-T Cell Therapy Market, by Thymic Cancer, by Region, 2019-2032 (USD Million)
- 6.12. Glioblastoma
- 6.12.1. Global CAR-T Cell Therapy Market, by Glioblastoma, by Region, 2019-2032 (USD Million)
- 6.13. AML
- 6.13.1. Global CAR-T Cell Therapy Market, by AML, by Region, 2019-2032 (USD Million)
- 6.14. Others
- 6.14.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2019-2032 (USD Million)
- 7. Global CAR-T Cell Therapy Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
- 7.3. CAR-T Cell Therapy Market – North America
- 7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.3.3. CAR-T Cell Therapy Market – U.S.
- 7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.3.4. CAR-T Cell Therapy Market – Canada
- 7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4. CAR-T Cell Therapy Market – Europe
- 7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.3. CAR-T Cell Therapy Market – UK
- 7.4.3.1. UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.3.2. UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.4. CAR-T Cell Therapy Market – France
- 7.4.4.1. France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.4.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.5. CAR-T Cell Therapy Market – Germany
- 7.4.5.1. Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.5.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.6. CAR-T Cell Therapy Market – Italy
- 7.4.6.1. Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.6.2. Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.7. CAR-T Cell Therapy Market – Spain
- 7.4.7.1. Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.7.2. Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.8. CAR-T Cell Therapy Market – Netherlands
- 7.4.8.1. Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.8.2. Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.4.9. CAR-T Cell Therapy Market – Russia
- 7.4.9.1. Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.4.9.2. Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5. CAR-T Cell Therapy Market – Asia Pacific
- 7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.3. CAR-T Cell Therapy Market – China
- 7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.4. CAR-T Cell Therapy Market – India
- 7.5.4.1. India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.4.2. India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.5. CAR-T Cell Therapy Market – Malaysia
- 7.5.5.1. Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.5.2. Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.6. CAR-T Cell Therapy Market – Japan
- 7.5.6.1. Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.6.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.7. CAR-T Cell Therapy Market – Indonesia
- 7.5.7.1. Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.7.2. Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.5.8. CAR-T Cell Therapy Market – South Korea
- 7.5.8.1. South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.5.8.2. South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.6. CAR-T Cell Therapy Market – Middle East & Africa
- 7.6.1. Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.6.2. Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.6.3. CAR-T Cell Therapy Market – Saudi Arabia
- 7.6.3.1. Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.6.3.2. Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.6.4. CAR-T Cell Therapy Market – UAE
- 7.6.4.1. UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.6.4.2. UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.6.5. CAR-T Cell Therapy Market – Israel
- 7.6.5.1. Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.6.5.2. Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.6.6. CAR-T Cell Therapy Market – South Africa
- 7.6.6.1. South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.6.6.2. South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.7. CAR-T Cell Therapy Market – Latin America
- 7.7.1. Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.7.2. Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.7.3. CAR-T Cell Therapy Market – Mexico
- 7.7.3.1. Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.7.3.2. Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.7.4. CAR-T Cell Therapy Market – Brazil
- 7.7.4.1. Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.7.4.2. Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 7.7.5. CAR-T Cell Therapy Market – Argentina
- 7.7.5.1. Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
- 7.7.5.2. Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. Amgen Inc. (US)
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Bellicum Pharmaceuticals, Inc
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Bellicum Pharmaceuticals, Inc. (US)
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Bluebird Bio (US)
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Caribou Biosciences, Inc. (US)
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Cellectis
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Celyad
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Gilead Sciences, Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Intellia Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Johnson & Johnson
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Merck KGaA
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. Nanjing Legend Biotechnology Co., Ltd
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Noile-Immune Biotech
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Novartis International AG
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Pfizer Inc
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
- 9.16. Sangamo Therapeutics, Inc
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
- 9.17. Servier Laboratories
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook